CAJ | 학술논문

目的：观察单磷酸阿糖腺苷治疗手足口病的疗效和安全性。方法：2013年1-12月收治手足口病患儿351例，按就诊顺序将其随机分为治疗组和对照组，治疗组176例给予单磷酸阿糖腺苷静滴，1次/d，对照组175例给予利巴韦林注射液静滴，1次/d，疗程均为5 d。观察两组临床症状及体征的变化及不良反应。结果：治疗组和对照组的总有效率分别为98.9%和88%，两组比较差异有统计学意义(P＜0.05)，治疗组未发现明显不良反应。结论：与利巴韦林相比，单磷酸阿糖腺苷治疗手足口病疗效显著，安全可靠，值得临床推广。
목적：관찰단린산아당선감치료수족구병적료효화안전성。방법：2013년1-12월수치수족구병환인351례，안취진순서장기수궤분위치료조화대조조，치료조176례급여단린산아당선감정적，1차/d，대조조175례급여리파위림주사액정적，1차/d，료정균위5 d。관찰량조림상증상급체정적변화급불량반응。결과：치료조화대조조적총유효솔분별위98.9%화88%，량조비교차이유통계학의의(P＜0.05)，치료조미발현명현불량반응。결론：여리파위림상비，단린산아당선감치료수족구병료효현저，안전가고，치득림상추엄。
Objective:To observe the efficacy and safety of vidarabine monophosphate in the treatment of hand foot mouth disease. Methods:351 patients with hand foot and mouth disease were selected from January to December 2013.They were randomly divided into the treatment group and the control group according to the order of treatment.176 cases in the treatment group were given vidarabine intravenous infusion,1 time/d.175 cases in the control group were given ribavirin injection intravenous infusion,1 time/d.The course of treatment both were 5 d.Then we observed the changes of the clinical symptoms,signs and adverse reaction between two groups.Results:The total effective rate of the treatment group and the control group were 98.9% and 88% respectively, and the difference was statistically significant between two groups(P<0.05).There was no obviously adverse reaction in the treatment group.Conclusion:Compare with ribavirin,the efficacy of vidarabine monophosphate is better in the treatment of hand foot mouth disease,and more safe and reliable,so it is worthy of clinical application.